

Fabrizio Bossa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4559072/publications.pdf>

Version: 2024-02-01

117
papers

4,572
citations

109321

35
h-index

106344

65
g-index

121
all docs

121
docs citations

121
times ranked

6844
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline Alterations in Patients With IBD-associated Colorectal Cancer. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 447-454.	1.9	6
2	Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology. <i>Digestive and Liver Disease</i> , 2022, 54, 440-451.	0.9	22
3	Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study. <i>United European Gastroenterology Journal</i> , 2021, 9, 102-109.	3.8	8
4	Interobserver agreement of the Paris and simplified classifications of superficial colonic lesions: a Western study. <i>Endoscopy International Open</i> , 2021, 09, E388-E394.	1.8	5
5	Transabdominal ultrasound-guided pancreatic biopsy: a neglected but safe, effective and inexpensive procedure that needs to be re-juvinalized. <i>Journal of Ultrasound</i> , 2021, 24, 175-182.	1.3	1
6	False-positive results of SARS-CoV-2 IgM/IgG antibody tests in sera stored before the 2020 pandemic in Italy. <i>International Journal of Infectious Diseases</i> , 2021, 104, 159-163.	3.3	26
7	Accuracy and inter-observer agreement of the nice and kudo classifications of superficial colonic lesions: a comparative study. <i>International Journal of Colorectal Disease</i> , 2021, 36, 1561-1568.	2.2	3
8	Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. <i>Digestive and Liver Disease</i> , 2021, 53, 277-282.	0.9	18
9	COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association. <i>Inflammatory Bowel Diseases</i> , 2021, , .	1.9	28
10	Effectiveness and Safety of A Nutraceutical Formulation for the Treatment of Functional Dyspepsia in Primary Care. <i>Reviews on Recent Clinical Trials</i> , 2021, 16, 329-334.	0.8	2
11	Inverted colonic diverticulum (ICD): report of two cases and literature review of a not that unusual endoscopic challenge. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101711.	1.5	2
12	One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1483-1489.	3.1	20
13	Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1432-1441.	3.7	11
14	Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 201-207.	1.6	8
15	Takotsubo Syndrome and Inflammatory Bowel Diseases: Does a Link Exist?. <i>Digestive Diseases</i> , 2020, 38, 204-210.	1.9	5
16	Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1767-1776.	2.3	11
17	microRNA-mRNA network model in patients with achalasia. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13764.	3.0	11
18	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e134-e136.	1.9	6

#	ARTICLE	IF	CITATIONS
19	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , 2020, 8, 1228-1235.	3.8	16
20	Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1579-1582.	1.6	9
21	Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. <i>Gut</i> , 2020, 69, 1213-1217.	12.1	283
22	Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 11356-11364.	0.7	1
23	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 568-579.	1.9	51
24	P.07.14 INTER-OBSERVER AGREEMENT OF ULCERATIVE COLITIS "EXTENDED MAYO ENDOSCOPIC SCORE (EMES)" WITHIN A MULTICENTER INFLAMMATORY BOWEL DISEASE (IBD) TEAM WORK. <i>Digestive and Liver Disease</i> , 2019, 51, e227-e228.	0.9	1
25	P.02.16 ROLE OF ABDOMINAL AND BOWEL ULTRASOUND IN LYNCH SYNDROME, FAMILIAL ADENOMATOUS POLYPOSIS AND OTHER MINOR HEREDITARY SYNDROMES. <i>Digestive and Liver Disease</i> , 2019, 51, e154-e155.	0.9	0
26	P.07.24 AZATHIOPRINE VS MESALAMINE FOR PREVENTION OF POST-OPERATIVE CLINICAL RELAPSE IN CROHN'S DISEASE PATIENTS WITH SEVERE ENDOSCOPIC RECURRENCE: DATA ON EFFICACY AND SAFETY FROM AN IG-IBD MULTICENTER RANDOMIZED DOUBLE-BLIND DOUBLE-DUMMY TRIAL. <i>Digestive and Liver Disease</i> , 2019, 51, e232.	0.9	0
27	Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn's disease. <i>Digestive and Liver Disease</i> , 2019, 51, 804-811.	0.9	3
28	Barriers to anti-TNFalpha prescription among Italian physicians managing inflammatory bowel disease. <i>GastroHep</i> , 2019, 1, 93-99.	0.6	3
29	A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. <i>Cells</i> , 2019, 8, 523.	4.1	10
30	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.9	36
31	Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease "AGED" study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1361-1369.	1.6	14
32	Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis. <i>Clinical and Experimental Immunology</i> , 2019, 196, 123-138.	2.6	27
33	Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2019, 51, 510-515.	0.9	18
34	Unmet needs of Italian physicians managing patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2019, 51, 212-217.	0.9	6
35	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 687-694.	1.3	10
36	Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 155, 829-843.	1.3	80

#	ARTICLE	IF	CITATIONS
37	P.02.10 REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD). <i>Digestive and Liver Disease</i> , 2018, 50, e136.	0.9	0
38	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.9	42
39	The PROSIT-BIO Cohort. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 233-243.	1.9	116
40	A Prolonged Follow-Up on the Efficacy and Safety of Infliximab Biosimilar CT-P13 in IBD Across Italy: The Prosit Cohort. <i>Gastroenterology</i> , 2017, 152, S108.	1.3	2
41	Nurse in patients' health status assessment: Data from a pilot study assessing agreement among nurse and gastroenterologist in computing IBD-clinical scores. <i>Digestive and Liver Disease</i> , 2017, 49, 1110-1114.	0.9	7
42	Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". <i>Digestive and Liver Disease</i> , 2017, 49, 17-23.	0.9	35
43	Addendum: Palmieri, O. et al. Functional Implications of MicroRNAs in Crohn's Disease Revealed by Integrating MicroRNA and Messenger RNA Expression Profiling. <i>Int. J. Mol. Sci.</i> 2017, 18, 1580. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2113.	4.1	0
44	Functional Implications of MicroRNAs in Crohn's Disease Revealed by Integrating MicroRNA and Messenger RNA Expression Profiling. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1580.	4.1	17
45	Crohn's Disease Localization Displays Different Predisposing Genetic Variants. <i>PLoS ONE</i> , 2017, 12, e0168821.	2.5	13
46	Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2017, 8, 131.	1.1	6
47	Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipation-predominant irritable bowel syndrome and functional constipation. <i>Neurogastroenterology and Motility</i> , 2016, 28, 581-591.	3.0	30
48	Gene expression of muscular and neuronal pathways is cooperatively dysregulated in patients with idiopathic achalasia. <i>Scientific Reports</i> , 2016, 6, 31549.	3.3	23
49	Transperineal ultrasonography: First level exam in IBD patients with perianal disease. <i>Digestive and Liver Disease</i> , 2016, 48, 874-879.	0.9	13
50	439 The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilar. <i>Gastroenterology</i> , 2016, 150, S92.	1.3	5
51	Tu1938 Endoscopic Training Leads to a Significant Increase in Agreement of Endoscopic Scoring for Inflammatory Bowel Disease (IBD): Final Results of the Igbidendo Educational Project. <i>Gastroenterology</i> , 2016, 150, S983-S984.	1.3	0
52	19 Infliximab Discontinuation Is Associated With a Higher Risk for Relapse in Patients With Ulcerative Colitis in Remission: A Multinational Collaborative Retrospective Study. <i>Gastroenterology</i> , 2016, 150, S6.	1.3	0
53	Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists. <i>Journal of Crohn's and Colitis</i> , 2016, 11, jjw181.	1.3	27
54	Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 174-175.	3.7	5

#	ARTICLE	IF	CITATIONS
55	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1426-1432.e1.	4.4	39
56	OC.11.7 MOTIVATIONAL INTERVIEWING IN OUTPATIENTS COUNSELLING: DATA FROM A LARGE CASE-CONTROL STUDY IN INFLAMMATORY BOWEL DISEASE PATIENTS. <i>Digestive and Liver Disease</i> , 2016, 48, e113-e114.	0.9	0
57	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 380-388.e4.	1.3	114
58	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	1.3	251
59	Randomised controlled trial of mesalazine in IBS. <i>Gut</i> , 2016, 65, 82-90.	12.1	91
60	Tu1156 Genome-Wide Expression Profiling of Idiopathic Achalasia Patients. <i>Gastroenterology</i> , 2015, 148, S-805-S-806.	1.3	0
61	Genome-wide Pathway Analysis Using Gene Expression Data of Colonic Mucosa in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	22
62	Systematic analysis of circadian genes using genome-wide cDNA microarrays in the inflammatory bowel disease transcriptome. <i>Chronobiology International</i> , 2015, 32, 903-916.	2.0	50
63	745 Methotrexate for Corticosteroid-Dependent Ulcerative Colitis: Results of a Placebo Randomized Controlled Trial. <i>Gastroenterology</i> , 2015, 148, S-140.	1.3	9
64	685 Risk Factor Analysis for Therapy Related Adverse Events and Infections in Elder Patients With Inflammatory Bowel Disease; An Analysis From the iG-IBD Aged Study. <i>Gastroenterology</i> , 2015, 148, S-133.	1.3	1
65	Su1073 The SOLE Survey: Disease Related Concerns of a Large Cohort of Italian Patients With Active Crohn's Disease. <i>Gastroenterology</i> , 2015, 148, S-400.	1.3	0
66	Mongersen, an Oral <i>SMAD7</i> Antisense Oligonucleotide, and Crohn's Disease. <i>New England Journal of Medicine</i> , 2015, 372, 1104-1113.	27.0	366
67	Whole Exome Sequencing of very early onset ulcerative colitis patients identifies new variants in candidate genes. <i>Digestive and Liver Disease</i> , 2015, 47, e257-e258.	0.9	0
68	Patient and physician views on the quality of care in inflammatory bowel disease: Results from SOLUTION-1, a prospective IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1642-1652.	1.3	27
69	Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1217-1221.	1.3	53
70	Sa1221 Increasing Interobserver Agreement on IBD Endoscopic Scoring Systems: Results From the IGIBDendo Educational Program. <i>Gastroenterology</i> , 2014, 146, S-234.	1.3	0
71	P.06.23 INFLIXIMAB IN STEROID-DEPENDENT ULCERATIVE COLITIS: LACK OF PREDICTIVE FACTORS FOR RESPONSE IN A LARGE MULTICENTER SERIES. <i>Digestive and Liver Disease</i> , 2014, 46, S78.	0.9	1
72	PC.01.8 INCREASING INTEROBSERVER AGREEMENT ON IBD ENDOSCOPIC SCORING SYSTEMS: RESULTS FROM THE IGIBDENDO EDUCATIONAL PROGRAM. <i>Digestive and Liver Disease</i> , 2014, 46, S4.	0.9	2

#	ARTICLE	IF	CITATIONS
73	Impact of genetic polymorphisms on the pathogenesis of idiopathic achalasia: Association with IL33 gene variant. <i>Human Immunology</i> , 2014, 75, 364-369.	2.4	8
74	Inter-observer agreement in endoscopic scoring systems: Preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2014, 46, 969-973.	0.9	78
75	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2014, 46, 963-968.	0.9	39
76	Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1371-1382.	2.3	7
77	Adalimumab in active ulcerative colitis: A "real-life" observational study. <i>Digestive and Liver Disease</i> , 2013, 45, 738-743.	0.9	72
78	Associations between Genetic Polymorphisms in IL-33, IL1R1 and Risk for Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2013, 8, e62144.	2.5	75
79	Erythrocytes-mediated Delivery of Dexamethasone 21-phosphate in Steroid-dependent Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	1.9	22
80	ImmunoChip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , 2012, 21, 5209-5221.	2.9	139
81	Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. <i>Genes and Immunity</i> , 2012, 13, 461-468.	4.1	75
82	Association Study of a Polymorphism in Clock Gene PERIOD3 and Risk of Inflammatory Bowel Disease. <i>Chronobiology International</i> , 2012, 29, 994-1003.	2.0	38
83	Neuroimmune interactions in patients with inflammatory bowel diseases: Disease activity and clinical behavior based on Substance P serum levels. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 563-570.	1.3	23
84	Dissection of the Crohn's Disease Transcriptome of 71 Loci Using Genome-Wide Microarrays. <i>Gastroenterology</i> , 2011, 140, S-272-S-273.	1.3	0
85	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 30-35.	4.4	316
86	IL23R, ATG16L1, IRGM, OCTN1, and OCTN2 mRNA expression in inflamed and noninflamed mucosa of IBD patients. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1832-1833.	1.9	7
87	Dissecting the mucosal expression of human leucine-rich repeat family genes in inflammatory bowel disease patients. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1834-1835.	1.9	1
88	Investigation of Multiple Susceptibility Loci for Inflammatory Bowel Disease in an Italian Cohort of Patients. <i>PLoS ONE</i> , 2011, 6, e22688.	2.5	53
89	Variants at the 3p21 locus influence susceptibility and phenotype both in adults and early-onset patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1108-1117.	1.9	22
90	How evidence-based are current guidelines for managing patients with peptic ulcer bleeding?. <i>World Journal of Gastrointestinal Surgery</i> , 2010, 2, 9.	1.5	1

#	ARTICLE	IF	CITATIONS
91	The A2518G Polymorphism of Monocyte Chemoattractant Protein-1 Is Associated With Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2010, 105, 1586-1594.	0.4	24
92	Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and <i>Clostridium difficile</i> infection. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 194-198.	1.3	78
93	Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: An IBD study. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 291-300.	1.3	21
94	The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases. <i>Digestive and Liver Disease Supplements</i> , 2010, 4, 1-3.	0.2	0
95	Long-term remission with adalimumab in steroid-dependent Crohn's disease patients with multiple drug intolerances. <i>Digestive and Liver Disease Supplements</i> , 2010, 4, 7-9.	0.2	1
96	Ulcerative colitis risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. <i>Nature Genetics</i> , 2009, 41, 216-220.	21.4	364
97	Combination Immunomodulator and Antibiotic Treatment in Patients With Inflammatory Bowel Disease and <i>Clostridium difficile</i> Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 981-987.	4.4	128
98	Treatment of steroid-naive ulcerative colitis. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1449-1460.	1.8	7
99	Linear IgA bullous dermatosis and Ulcerative colitis treated by proctocolectomy. <i>European Journal of Dermatology</i> , 2009, 19, 651-651.	0.6	10
100	Enteropathic spondyloarthropathy: A common genetic background with inflammatory bowel disease?. <i>World Journal of Gastroenterology</i> , 2009, 15, 2456.	3.3	21
101	New biologics in the management of Crohn's disease: focus on certolizumab pegol. <i>Clinical and Experimental Gastroenterology</i> , 2009, 2, 61-8.	2.3	3
102	The association of MYO9B gene in Italian patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 241-248.	3.7	31
103	Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study. <i>American Journal of Gastroenterology</i> , 2008, 103, 2509-2516.	0.4	66
104	Replication of interleukin 23 receptor and autophagy-related 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy. <i>World Journal of Gastroenterology</i> , 2008, 14, 4643.	3.3	66
105	Polymorphisms of Tumor Necrosis Factor but Not MDR1 Influence Response to Medical Therapy in Pediatric Onset Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2007, 44, 171-179.	1.8	76
106	Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial. <i>American Journal of Gastroenterology</i> , 2007, 102, 601-608.	0.4	95
107	Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGR3 genes in inflammatory bowel disease: A meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1212-1219.	1.9	35
108	Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 737-745.	3.7	41

#	ARTICLE	IF	CITATIONS
109	Detection of abnormal lesions recorded by capsule endoscopyA prospective study comparing endoscopist's and nurse's accuracy. Digestive and Liver Disease, 2006, 38, 599-602.	0.9	44
110	Variants of OCTN1â€“2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2006, 23, 497-506.	3.7	57
111	Erythrocytes as a controlled drug delivery system: Clinical evidences. Journal of Controlled Release, 2006, 116, e43-e45.	9.9	12
112	Multidrug resistance 1 gene in inflammatory bowel disease: A meta-analysis. World Journal of Gastroenterology, 2006, 12, 3636.	3.3	125
113	Worse clinical course of disease in Crohn's patients with previous appendectomy. European Journal of Gastroenterology and Hepatology, 2005, 17, 623-627.	1.6	12
114	Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Alimentary Pharmacology and Therapeutics, 2005, 22, 1129-1138.	3.7	60
115	Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study. Digestive and Liver Disease, 2005, 37, 577-583.	0.9	75
116	Colorectal cancer and high grade dysplasia complicating ulcerative colitis in Italy. Digestive and Liver Disease, 2003, 35, 628-634.	0.9	11
117	Presentation of colorectal cancer in patients with ulcerative colitis: A GISC-GTSMII multicenter investigation. Gastroenterology, 2000, 118, A1408.	1.3	0